WINDTREE THERAPEUTICS INC /DE/ Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | — | — | -$28.1M | — | -$19.9M | -$1.08 |
| Q2 FY202510-Q · 2025-06-30 | — | — | $0 | — | -$4.0M | -$3.06 |
| Q1 FY202510-Q · 2025-03-31 | — | — | $0 | — | -$4.1M | -$4.63 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $16.0M | $27.6M | $204.0K | -$11.6M |
| Q2 FY202510-Q | $31.8M | $25.0M | $301.0K | $9.0K |
| Q1 FY202510-Q | $26.8M | $15.4M | $1.2M | $4.0K |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | -$19.9M | -$28.1M | — | 33,634,220 |
| Q2 FY202510-Q | -$4.0M | $0 | — | 9,247,952 |
| Q1 FY202510-Q | -$4.1M | $0 | — | 3,555,953 |
Filings
(4)Methodology
Every figure on this page is pulled directly from WINDTREE THERAPEUTICS INC /DE/'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].